Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group

Next Previous
Trial Profile

International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epratuzumab (Primary) ; Asparaginase; Asparaginase; Crisantaspase; Crisantaspase; Cyclophosphamide; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Idarubicin; Ifosfamide; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Mitoxantrone; Prednisolone; Tioguanine; Vincristine; Vindesine
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms IntReALL SR 2010

    • Most Recent Events

    • 21 Feb 2024 This trial has been completed in Czech Republic. (Global end date: 31 July 2023).
    • 31 Jan 2024 This trial has been completed in Belgium, according to European Clinical Trials Database record.
    • 16 Jan 2024 This trial has been completed in Finland, according to European Clinical Trials Database record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top